Press release
Polycystic Kidney Disease Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments by Delveinsight
Polycystic Kidney Disease Pipeline
Polycystic Kidney Disease Overview
Polycystic kidney disease (PKD) is a genetic disease (passed from an affected parent to their child) causing uncontrolled growth of cysts in the kidney eventually leading to kidney failure. While the disease affects all races and ethnicities equally, data suggests African Americans suffer worse outcomes due to delayed diagnosis, slower referrals to nephrology specialists than their white counterparts, and earlier progression to end-stage renal disease as a result.
"Polycystic Kidney Disease Pipeline Insight, 2022" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Polycystic Kidney Disease Market.
The Polycystic Kidney Disease Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Polycystic Kidney Disease Pipeline Report: https://www.delveinsight.com/report-store/polycystic-kidney-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
• Companies across the globe are diligently working toward developing novel Polycystic Kidney Disease treatment therapies with a considerable amount of success over the years. Polycystic Kidney Disease Key players such as - AmMax Bio, AceLink Therapeutics, Kadmon Pharmaceuticals, Galapagos NV, Centessa Pharmaceuticals, Reata Pharmaceuticals, and others, are developing therapies for the Polycystic Kidney Disease treatment
• Polycystic Kidney Disease Emerging therapies such as - AMB-05X, AL01211, Tesevatinib, GLPG2737, Lixivaptan, Bardoxolone methyl, and others are expected to have a significant impact on the Polycystic Kidney Disease market in the coming years.
• Reata Pharmaceuticals initiated a Phase III trial of Bardoxolone Methyl in patients with autosomal dominant polycystic kidney disease. This international, multi-center, randomized, double-blind, placebo-controlled Phase3 trial will study the safety, tolerability, and efficacy of bardoxolone methyl in qualified patients with ADPKD.
• The FDA and European Commission had granted Orphan Drug designation to bardoxolone for the treatment of Alport syndrome and autosomal dominant polycystic kidney disease ("ADPKD").
Polycystic Kidney Disease Pipeline Therapeutics Assessment
• Polycystic Kidney Disease Assessment by Product Type
• Polycystic Kidney Disease By Stage and Product Type
• Polycystic Kidney Disease Assessment by Route of Administration
• Polycystic Kidney Disease By Stage and Route of Administration
• Polycystic Kidney Disease Assessment by Molecule Type
• Polycystic Kidney Disease by Stage and Molecule Type
DelveInsight's Polycystic Kidney Disease Report covers around 22+ products under different phases of clinical development like
• Late-stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I)
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates
• Route of Administration
Emerging Polycystic Kidney Disease Drugs Under Different Phases of Clinical Development Include:
• AMB-05X: AmMax Bio
• AL01211: AceLink Therapeutics
• Tesevatinib: Kadmon Pharmaceuticals
• GLPG2737: Galapagos NV
• Lixivaptan: Centessa Pharmaceuticals
• Bardoxolone methyl: Reata Pharmaceuticals
Get a Free Sample PDF Report to know more about Polycystic Kidney Disease Pipeline Assessment- https://www.delveinsight.com/sample-request/polycystic-kidney-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Polycystic Kidney Disease Pipeline Analysis:
The Polycystic Kidney Disease pipeline report provides insights into
• The report provides detailed insights about companies that are developing therapies for the Polycystic Kidney Disease treatment with aggregate therapies developed by each company for the same.
• It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Polycystic Kidney Disease Treatment.
• Polycystic Kidney Disease key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
• Polycystic Kidney Disease Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
• Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Polycystic Kidney Disease market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Further Polycystic Kidney Disease product details are provided in the report. Download the Polycystic Kidney Disease pipeline report to learn more about the emerging Polycystic Kidney Disease therapies at:
https://www.delveinsight.com/sample-request/polycystic-kidney-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Polycystic Kidney Disease Pipeline Market Drivers
• Increase in the number of research and development activities
• Rising investment for the development of advanced technologies
Polycystic Kidney Disease Pipeline Market Barriers
• High cost associated with the treatment
• Lack of healthcare infrastructure in developing economies
Scope of Polycystic Kidney Disease Pipeline Drug Insight
• Coverage: Global
• Key Polycystic Kidney Disease Companies: AmMax Bio, AceLink Therapeutics, Kadmon Pharmaceuticals, Galapagos NV, Centessa Pharmaceuticals, Reata Pharmaceuticals, and others
• Key Polycystic Kidney Disease Therapies: AMB-05X, AL01211, Tesevatinib, GLPG2737, Lixivaptan, Bardoxolone methyl, and others
• Polycystic Kidney Disease Therapeutic Assessment: Polycystic Kidney Disease current marketed and Polycystic Kidney Disease emerging therapies
• Polycystic Kidney Disease Market Dynamics: Polycystic Kidney Disease market drivers and Polycystic Kidney Disease market barriers
Request for Sample PDF Report for Polycystic Kidney Disease Pipeline Assessment and clinical trials- https://www.delveinsight.com/sample-request/polycystic-kidney-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Table of Contents
1 Polycystic Kidney Disease Report Introduction
2 Polycystic Kidney Disease Executive Summary
3 Polycystic Kidney Disease Overview
4 Polycystic Kidney Disease- Analytical Perspective In-depth Commercial Assessment
5 Polycystic Kidney Disease Pipeline Therapeutics
6 Polycystic Kidney Disease Late Stage Products (Phase II/III)
7 Polycystic Kidney Disease Mid Stage Products (Phase II)
8 Polycystic Kidney Disease Early Stage Products (Phase I)
9 Polycystic Kidney Disease Preclinical Stage Products
10 Polycystic Kidney Disease Therapeutics Assessment
11 Polycystic Kidney Disease Inactive Products
12 Company-University Collaborations (Licensing/Partnering) Analysis
13 Polycystic Kidney Disease Key Companies
14 Polycystic Kidney Disease Key Products
15 Polycystic Kidney Disease Unmet Needs
16 Polycystic Kidney Disease Market Drivers and Barriers
17 Polycystic Kidney Disease Future Perspectives and Conclusion
18 Polycystic Kidney Disease Analyst Views
19 Appendix
20 About DelveInsight
Download Sample PDF Report to know more about Polycystic Kidney Disease drugs and therapies- https://www.delveinsight.com/sample-request/polycystic-kidney-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Related Reports:
Polycystic Kidney Disease Market https://www.delveinsight.com/report-store/polycystic-kidney-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Polycystic Kidney Disease-Market Insights, Epidemiology, and Market Forecast-2032' report delivers an in-depth understanding of the 7MM, historical and forecasted epidemiology as well as the 7MM market trends in the United States, EU5 (Germany, France, Italy, Spain, and United Kingdom),
Polycystic Kidney Disease Epidemiology https://www.delveinsight.com/report-store/polycystic-kidney-disease-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'Polycystic Kidney Disease Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted Cholangiocarcinoma epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
Contact Us:
Gaurav Bora
gbora@delveinsight.com
+1(919)321-6187
https://www.delveinsight.com/consulting
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Polycystic Kidney Disease Pipeline Drugs and Companies Insight Report (2022): Analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments by Delveinsight here
News-ID: 2852686 • Views: …
More Releases from DelveInsight Business Research
Spinocerebellar Ataxias Pipeline 2025: Comprehensive Clinical Trials and Therapi …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Spinocerebellar Ataxias pipeline constitutes 8+ key companies continuously working towards developing 10+ Spinocerebellar Ataxias treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight.
"Spinocerebellar Ataxias Pipeline Insight, 2025" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Spinocerebellar Ataxias Market.
The Spinocerebellar…
Presbyopia Market to Evolve Rapidly Over the Next Decade by 2034, DelveInsight O …
The Presbyopia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Presbyopia pipeline products will significantly revolutionize the Presbyopia market dynamics.
DelveInsight's "Presbyopia Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Presbyopia, historical and forecasted epidemiology as well as the Presbyopia market trends in the United States, EU5 (Germany, Spain, Italy, France,…
Idiopathic Pulmonary Fibrosis Market Insights Highlight Expanding Outlook Till 2 …
DelveInsight's "Idiopathic Pulmonary Fibrosis Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Idiopathic Pulmonary Fibrosis, historical and forecasted epidemiology as well as the Idiopathic Pulmonary Fibrosis market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
The latest healthcare forecast report provides an in-depth analysis of Idiopathic Pulmonary Fibrosis, offering comprehensive insights into the Idiopathic Pulmonary Fibrosis revenue trends,…
Myocardial Infarction Market Positioned for Accelerated Development Through 2034 …
DelveInsight's "Myocardial Infarction Market Insights, Epidemiology, and Market Forecast-2034′′ report offers an in-depth understanding of the Myocardial Infarction, historical and forecasted epidemiology as well as the Myocardial Infarction market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Myocardial Infarction market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Myocardial Infarction Market Forecast
https://www.delveinsight.com/sample-request/myocardial-infarction-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
Some of the…
More Releases for Polycystic
Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market Research
The Global Autosomal Dominant Polycystic Kidney Disease (ADPKD) Market reached with a CAGR during the forecast period 2024-2031.
Autosomal Dominant Polycystic Kidney Disease Market, as detailed in the DataM Intelligence report, presents a strategic overview of the industry backed by in-depth data and market trends. The study highlights the performance and positioning of major players, focusing on their offerings, pricing models, financial outcomes, and growth strategies. It serves as a concise…
Global Efforts to Address Polycystic Ovarian Syndrome (PCOS) Gain Momentum
The Polycystic Ovarian Syndrome (PCOS) Treatment Market is expected to grow from an estimated USD 3514.5 million in 2024 to USD 5546.3 million in 2033, at a CAGR of 5.20%. Global initiatives to raise awareness and address Polycystic Ovarian Syndrome (PCOS) are making significant strides in improving women's health. The World Health Organization (WHO) highlights PCOS as a critical health disorder due to its impact on reproductive health, metabolic well-being,…
Polycystic Kidney Disease Treatment Comprehensive Analysis and Future Estimation …
According to Fact.MR, Insights of Polycystic Kidney Disease Treatment is a specialized and in-depth study of the industry with a special focus on the Key Trends of Polycystic Kidney Disease Treatment as a Service. The report aims to provide an overview with detailed segmentation by type, application, end use and geography. The global is expected to witness high growth during the forecast period.
A survey offers detailed analysis on key growth…
Polycystic Ovarian Syndrome Treatment Market Report
The findings reviewed by GME stated that the Global Polycystic Ovarian Syndrome Treatment Market will expand with a CAGR value of 5.2 percent from 2021 to 2026. The rising incidence of PCOS increased understanding among a group of patients, and the growing acceptance of standard treatment boosts the PCOS treatment industry growth over the projected timeframe. Furthermore, the research and development of PCOS are predicted to aid in market growth.
Browse…
Global Polycystic Ovary Syndrome Market Trends, Size, Forecast - 2018-2023
Polycystic ovary syndrome is a hormonal disorder observed in females of reproductive ages. The disorder causes the excessive production of hormones in the female body, which include testosterone or androgens, hormones that are primarily associated with the male reproductive system. PCOS includes a range of symptoms such as irregular menstrual cycle, trouble in getting pregnant, cyst formation in the ovaries, excessive body and facial hair, and pelvic pain, among…
Polycystic Ovarian Syndrome Treatment Market - Regional Analysis
The organic and inorganic strategies by the market players will boost the polycystic ovarian syndrome treatment market. For instance, in 2016, Millendo Therapeutics, Inc., a biopharmaceutical company, entered into an exclusive license agreement with AstraZeneca for the development and commercialization of phase II entered AZD4901, a candidate product for the treatment of polycystic ovarian syndrome. Moreover, in 2017, Astellas Pharma Inc. completed its acquisition of Ogeda SA (formerly Euroscreen S.A.).…
